Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T22:03:15.008Z Has data issue: false hasContentIssue false
  • English
  • Français

Anticholinergics for urge incontinence

Part of: Bespoke shallow archive Weizmann

Published online by Cambridge University Press:  18 February 2010

R Mappilakkandy  and
AK Mistri
R Mappilakkandy
Affiliation:
University Hospitals of Leicester NHS Trust and Ageing & Stroke Medicine, Department of Cardiovascular Sciences, University of Leicester, UK
AK Mistri*
Affiliation:
University Hospitals of Leicester NHS Trust and Ageing & Stroke Medicine, Department of Cardiovascular Sciences, University of Leicester, UK
*
Address for correspondence: Dr AK Mistri, Ageing & Stroke Medicine, Department of Cardiovascular Sciences, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Urinary incontinence is a common symptom in women, more so in older people, with a significant impact on physical health and wellbeing. About 1 in 5 people have impaired continence. Symptom categorization at initial assessment is the key to guiding further therapy. Non-pharmacological options (bladder training for 6 weeks with guidance from a trained physiotherapist) are preferred and can be supported with biofeedback. If unsuccessful, anticholinergics are added and, rarely, surgical options need consideration.

Anticholinergics are the mainstay of pharmacological management of urge incontinence. The National Institute of Health and Clinical Excellence (NICE) recommends immediate release oxybutynin as the first-line agent, with recourse to others if there are adverse effects. The pharmacology, efficacy and adverse effect profile of the various anticholinergic drugs is reviewed, allowing the reader to make an informed choice of appropriate anticholinergics for urge incontinence.

Keywords

agedanticholinergicsurge incontinenceoveractive bladderurinary incontinence
Type
Clinical geriatrics
Information
Reviews in Clinical Gerontology , Volume 20 , Issue 1 , February 2010 , pp. 30 - 41
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Wagner, TH, Hu, TW, Bentkover, J et al. Health-related consequences of overactive bladder. Am J Manag Care 2002; 8 (suppl): S598–607.Google ScholarPubMed
2Brown, JS, McGhan, WF, Chokroverty, S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (suppl): S574–79.Google ScholarPubMed
3Brown, JS, Vittinghoff, E, Wyman, JF et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721–25.CrossRefGoogle ScholarPubMed
4Turner, DA, Shaw, C, McGrother, CW et al. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004; 93: 1246–52.CrossRefGoogle ScholarPubMed
5Abrams, P, Cardozo, L, Fall, M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.CrossRefGoogle ScholarPubMed
6Hannestad, YS, Rortveit, G, Sandvik, H et al. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000; 53: 1150–57.CrossRefGoogle ScholarPubMed
7McGrother, CW, Donaldson, MM, Hayward, T et al. Urinary storage symptoms and comorbidities: a prospective population cohort study in middle-aged and older women. Age Ageing 2006; 35: 16–24.CrossRefGoogle ScholarPubMed
8Minassian, VA, Drutz, HP, Al Badr, A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet 2003; 82: 327–38.CrossRefGoogle ScholarPubMed
9National Institute for Clinical Excellence. Sacral Nerve Stimulation for Urge Incontinence and Urgency-Frequency. 2004.Google Scholar
10Kelleher, C, Cortes, E. Defining success in overactive bladder: the importance of patient-focused outcomes. Br J Obstet Gynaecol 2006; 113: 9–18.CrossRefGoogle Scholar
11National Collaborating Centre for Women's and Children's Health. The Management of Urinary Incontinence in Women. 2006.Google Scholar
12Fantl, JA, Wyman, JF, McClish, DK et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265: 609–13.CrossRefGoogle ScholarPubMed
13Jarvis, GJ, Millar, DR. Controlled trial of bladder drill for detrusor instability. Br Med J 1980; 281: 1322–23.CrossRefGoogle ScholarPubMed
14Fick, DM, Cooper, JW, Wade, WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716–24.CrossRefGoogle ScholarPubMed
15Hashim, H, Abrams, P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004; 64: 1643–56.CrossRefGoogle ScholarPubMed
16Chapple, C. The contemporary pharmacological management of overactive bladder. Br J Obstet Gynaecol 2006; 113: 19–28.CrossRefGoogle Scholar
17Szonyi, G, Collas, DM, Ding, YY et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995; 24: 287–91.CrossRefGoogle ScholarPubMed
18Burgio, KL, Locher, JL, Roth, DL et al. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. J Gerontol B Psychol Sci Soc Sci 2001; 56: 46–51.CrossRefGoogle ScholarPubMed
19Thuroff, JW, Chartier-Kastler, E, Corcus, J et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1998; 16: S48–61.CrossRefGoogle ScholarPubMed
20Kelleher, CJ, Cardozo, LD, Khullar, V et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988–93.CrossRefGoogle ScholarPubMed
21Katz, IR, Sands, LP, Bilker, W et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 8–13.CrossRefGoogle ScholarPubMed
22Donnellan, CA, Fook, L, McDonald, P et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315: 1363–64.CrossRefGoogle ScholarPubMed
23Appell, RA, Sand, P, Dmochowski, R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358–63.CrossRefGoogle ScholarPubMed
24Diokno, AC, Appell, RA, Sand, PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78: 687–95.CrossRefGoogle ScholarPubMed
25Lackner, TE, Wyman, JF, McCarthy, TC et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008; 56: 862–70.CrossRefGoogle ScholarPubMed
26Davila, GW, Daugherty, CA, Sanders, SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140–45.CrossRefGoogle ScholarPubMed
27Sand, P, Zinner, N, Newman, D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836–44.CrossRefGoogle ScholarPubMed
28Cartwright, R, Cardozo, L. Transdermal oxybutynin: sticking to the facts. Eur Urol 2007; 51: 907–14.CrossRefGoogle Scholar
29Saito, M, Tabuchi, F, Otsubo, K et al. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn 2000; 19: 683–88.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
30Van Kerrebroeck, P, Kreder, K, Jonas, U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57: 414–21.CrossRefGoogle ScholarPubMed
31Appell, RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50: 90–96.CrossRefGoogle ScholarPubMed
32Zinner, NR, Mattiasson, A, Stanton, SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799–807.CrossRefGoogle ScholarPubMed
33Rackley, R, Weiss, JP, Rovner, ES et al. Night-time dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006; 67: 731–36.CrossRefGoogle Scholar
34Rovner, ES. Trospium chloride in the management of overactive bladder. Drugs 2004; 64: 2433–46.CrossRefGoogle ScholarPubMed
35Cardozo, L, Chapple, CR, Toozs-Hobson, P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659–64.CrossRefGoogle ScholarPubMed
36Rudy, D, Cline, K, Harris, R et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275–80.CrossRefGoogle ScholarPubMed
37Staskin, D, Sand, P, Zinner, N et al. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007; 178: 978–83.CrossRefGoogle ScholarPubMed
38Chapple, C, Steers, W, Norton, P et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95: 993–1001.CrossRefGoogle ScholarPubMed
39Zinner, N, Kobashi, KC, Ebinger, U et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008; 62: 1664–74.CrossRefGoogle ScholarPubMed
40Dwyer, P, Kelleher, C, Young, J et al. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn 2008; 27: 540–47.CrossRefGoogle ScholarPubMed
41Hill, S, Khullar, V, Wyndaele, JJ et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 239–47.CrossRefGoogle ScholarPubMed
42Kay, GG, Ebinger, U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008; 62: 1792–1800.CrossRefGoogle ScholarPubMed
43Serra, DB, Affrime, MB, Bedigian, MP et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005; 45: 1038–47.CrossRefGoogle ScholarPubMed
44Karram, MM, Toglia, MR, Serels, SR et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73: 14–18.CrossRefGoogle Scholar
45Staskin, DR, Te, AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006; 97: 1256–61.CrossRefGoogle Scholar
46Chapple, CR, Cardozo, L, Steers, WD et al. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006; 60: 959–66.CrossRefGoogle ScholarPubMed
47Cardozo, L, Hessdorfer, E, Milani, R et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 1120–27.CrossRefGoogle ScholarPubMed
48Brubaker, L, FitzGerald, MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 737–41.CrossRefGoogle ScholarPubMed
49Chapple, CR, Martinez-Garcia, R, Selvaggi, L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464–70.CrossRefGoogle ScholarPubMed
50Wagg, A, Wyndaele, JJ, Sieber, P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14–24.CrossRefGoogle ScholarPubMed
51Pelman, RS, Capo, JP Jr, Forero-Schwanhaeuser S. Solifenacin at 3 years: a review of efficacy and safety. Postgrad Med 2008; 120: 85–91.CrossRefGoogle Scholar
52Staskin, DR, Dmochowski, RR, Sand, PK et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009; 181: 1764–72.CrossRefGoogle ScholarPubMed
53Chapple, CR, Van Kerrebroeck, PE, Junemann, KP et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 2008; 102: 1128–32.CrossRefGoogle ScholarPubMed
54Simon, HU, Malhotra, B. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. Swiss Med Wkly 2009; 139: 146–51.Google ScholarPubMed
55Homma, Y, Yamaguchi, O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2008; 15: 986–91.CrossRefGoogle ScholarPubMed
56Guest, JF, Abegunde, D, Ruiz, FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig 2004; 24: 305–21.CrossRefGoogle ScholarPubMed
57Chapple, CR, Rosenberg, MT, Brenes, FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009; 104: 960–67.CrossRefGoogle Scholar